Uwell Biopharma, Inc. (TPEX:7902)
44.30
+0.20 (0.45%)
At close: Mar 9, 2026
Uwell Biopharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
| Cash & Equivalents | 220.31 | 43.4 | 23.09 | 27.71 | 94.54 | 3.68 |
| Short-Term Investments | - | 4.5 | 63 | - | - | - |
| Cash & Short-Term Investments | 220.31 | 47.9 | 86.09 | 27.71 | 94.54 | 3.68 |
| Cash Growth | 695.07% | -44.37% | 210.70% | -70.69% | 2469.64% | - |
| Other Receivables | 0.03 | 0.04 | 0.07 | 0 | 1.44 | 0.7 |
| Receivables | 0.03 | 0.04 | 0.07 | 0 | 1.44 | 0.7 |
| Prepaid Expenses | 0.44 | 0.46 | 0.71 | 0.48 | - | - |
| Other Current Assets | 0.02 | 0.09 | 0.05 | 0.27 | 1.38 | 1.29 |
| Total Current Assets | 220.79 | 48.48 | 86.91 | 28.46 | 97.36 | 5.67 |
| Property, Plant & Equipment | 16.73 | 19.56 | 25.48 | 26.6 | 5 | 0.11 |
| Other Intangible Assets | 0.02 | 0.04 | 0.09 | 0.23 | - | - |
| Other Long-Term Assets | 8.19 | 8.08 | 6.04 | 5.11 | 1.26 | 0.01 |
| Total Assets | 245.73 | 76.16 | 118.51 | 60.4 | 103.61 | 5.79 |
| Accrued Expenses | 12.09 | 5.36 | 4.42 | 5.62 | 3.43 | 1.59 |
| Current Portion of Leases | 2.57 | 4.25 | 4.14 | 3.4 | 2.35 | - |
| Other Current Liabilities | 0.95 | 1.09 | 0.49 | 0.8 | 0.26 | 0.2 |
| Total Current Liabilities | 15.61 | 10.7 | 9.05 | 9.81 | 6.03 | 1.79 |
| Long-Term Leases | - | 0.86 | 3.98 | 4.95 | 1.01 | - |
| Total Liabilities | 15.61 | 11.56 | 13.03 | 14.76 | 7.04 | 1.79 |
| Common Stock | 117 | 117 | 117 | 57 | 171.8 | 58.6 |
| Additional Paid-In Capital | 153.08 | 2.54 | 47.54 | 2.54 | 0.65 | 0.65 |
| Retained Earnings | -90.3 | -55.3 | -59.43 | -14.26 | -78.79 | -58.31 |
| Comprehensive Income & Other | 50.35 | 0.38 | 0.38 | 0.37 | 2.91 | 3.06 |
| Shareholders' Equity | 230.13 | 64.61 | 105.48 | 45.64 | 96.57 | 4 |
| Total Liabilities & Equity | 245.73 | 76.16 | 118.51 | 60.4 | 103.61 | 5.79 |
| Total Debt | 2.57 | 5.11 | 8.12 | 8.34 | 3.36 | - |
| Net Cash (Debt) | 217.73 | 42.79 | 77.98 | 19.37 | 91.18 | 3.68 |
| Net Cash Growth | 1024.36% | -45.13% | 302.67% | -78.76% | 2378.42% | - |
| Net Cash Per Share | 1.86 | 0.37 | 0.88 | 0.34 | 5.53 | 0.57 |
| Filing Date Shares Outstanding | 117 | 117 | 117 | 57 | 21.2 | 6.45 |
| Total Common Shares Outstanding | 117 | 117 | 117 | 57 | 21.2 | 6.45 |
| Working Capital | 205.18 | 37.79 | 77.86 | 18.65 | 91.32 | 3.88 |
| Book Value Per Share | 1.97 | 0.55 | 0.90 | 0.80 | 4.56 | 0.62 |
| Tangible Book Value | 230.1 | 64.57 | 105.4 | 45.41 | 96.57 | 4 |
| Tangible Book Value Per Share | 1.97 | 0.55 | 0.90 | 0.80 | 4.56 | 0.62 |
| Machinery | 16.44 | 16.44 | 16.44 | 14.44 | 1.81 | 0.19 |
| Leasehold Improvements | 9.32 | 9.32 | 9.32 | 9.32 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.